Among the South Korean firms presenting to last week's virtual J.P. Morgan Healthcare Conference, Hanmi Pharmaceutical Co., Ltd. highlighted its global strategy and roadmap related to COVID-19, including preparations to manufacture mRNA and DNA vaccines, along with its new drug development strategy for the year.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?